| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. | Chief Medical Officer | Stock Option (Right to Buy) | 92,300 | 06 Mar 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics, Inc. | 06 Mar 2025 | 1 | $0 | 4 | Chief Medical Officer | 10 Mar 2025, 19:58 |
| FDMT | 4D Molecular Therapeutics, Inc. | 07 Feb 2024 | 0 | $0 | 3/A | Chief Medical Officer | 07 Feb 2024, 19:42 |
| FDMT | 4D Molecular Therapeutics, Inc. | 05 Feb 2024 | 10 | -$370,948 | 4 | Chief Medical Officer | 07 Feb 2024, 20:32 |
| FDMT | 4D Molecular Therapeutics, Inc. | 11 Dec 2023 | 1 | $0 | 4 | Chief Medical Officer | 13 Dec 2023, 16:05 |
| FDMT | 4D Molecular Therapeutics, Inc. | 24 Mar 2023 | 0 | $0 | 3 | Chief Medical Officer | 05 Apr 2023, 21:28 |